keyword
MENU ▼
Read by QxMD icon Read
search

yellow fever vaccine

keyword
https://www.readbyqxmd.com/read/28925936/an-atypical-local-vesicular-reaction-to-the-yellow-fever-vaccine
#1
Robert H Wauters, Camellia L Hernandez, Maureen M Petersen
Yellow fever vaccine is a live attenuated viral inoculation indicated for patients traveling to endemic areas. The vaccine is generally well tolerated with minimal adverse effects. Typical side effects include malaise, pain at the injection site, and, albeit rarely, immediate hypersensitivity reactions. We present a case of a rare adverse reaction to yellow fever vaccine in which a patient developed vesicular lesions resulting in bullae and circumferential hyperpigmentation.
September 19, 2017: Vaccines
https://www.readbyqxmd.com/read/28903515/update-from-the-advisory-committee-on-immunization-practices
#2
Sean T O'Leary, Yvonne A Maldonado, Carrie L Byington
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (C...
September 1, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28893288/potential-contribution-of-gut-microbiota-and-systemic-inflammation-on-hiv-vaccine-effectiveness-and-vaccine-design
#3
REVIEW
Jean-Pierre Routy, Vikram Mehraj
The quest for an effective HIV-1 vaccine began as soon as the virus causing AIDS was identified. After several disappointing attempts, results of the Phase-III RV144 trial in Thailand were a beacon of hope for the field demonstrating correlation between protection and immunological markers. In order to optimize vaccine response, we underline results from yellow fever and hepatitis B vaccines, where protective responses were predicted by the pre-vaccination level of immune activation in healthy individuals. Such findings support the assessment and reduction of pre-vaccine immune activation in order to optimize vaccine response...
September 12, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28885461/vaccinations-and-malaria-chemoprophylaxis-of-adolescents-traveling-from-greece-to-international-destinations-a-nine-year-prospective-study
#4
Helena C Maltezou, Androula Pavli, Kalliopi Theodoridou, Panos Katerelos, Athina Spilioti, Anastasia Tedoma, Ioanna Lymperi, Maria Theodoridou
BACKGROUND: There are few publications focusing on vaccination and malaria chemoprophylaxis in adolescent travelers. We assessed pre-travel vaccinations and malaria chemoprophylaxis of adolescents 12-18 old traveling from Greece to international destinations. METHODS: We prospectively studied 239 adolescents 12-18 years old during 2008-2016. A standard questionnaire was used to collect data. RESULTS: Adolescents sought pre-travel services at a mean of 24...
September 6, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28869941/identifying-attenuating-mutations-tools-for-a-new-vaccine-design-against-flaviviruses
#5
Cécile Khou, Nathalie Pardigon
Emerging Flaviviruses pose an increasing threat to global human health. To date, human vaccines against yellow fever virus (YFV), Japanese encephalitis virus (JEV), dengue virus (DV), and tick-borne encephalitis virus (TBEV) exist. However, there is no human vaccine against other Flaviviruses such as Zika virus (ZIKV) and West Nile virus (WNV). In order to restrict their spread and to protect populations against the diseases they induce, vaccines against these emerging viruses must be designed. Obtaining new live attenuated Flavivirus vaccines using molecular biology methods is now possible...
September 5, 2017: Intervirology
https://www.readbyqxmd.com/read/28867843/estimated-economic-impact-of-vaccinations-in-73-low-and-middle-income-countries-2001-2020
#6
Sachiko Ozawa, Samantha Clark, Allison Portnoy, Simrun Grewal, Meghan L Stack, Anushua Sinha, Andrew Mirelman, Heather Franklin, Ingrid K Friberg, Yvonne Tam, Neff Walker, Andrew Clark, Matthew Ferrari, Chutima Suraratdecha, Steven Sweet, Sue J Goldie, Tini Garske, Michelle Li, Peter M Hansen, Hope L Johnson, Damian Walker
OBJECTIVE: To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. METHODS: We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever...
September 1, 2017: Bulletin of the World Health Organization
https://www.readbyqxmd.com/read/28838191/expansion-of-surveillance-for-vaccine-preventable-diseases-building-on-the-global-polio-laboratory-network-and-the-global-measles-and-rubella-laboratory-network-platforms
#7
Mick N Mulders, Fatima Serhan, James L Goodson, Joseph Icenogle, Barbara W Johnson, Paul A Rota
Laboratory networks were established to provide accurate and timely laboratory confirmation of infections, an essential component of disease surveillance systems. The World Health Organization (WHO) coordinates global laboratory surveillance of vaccine-preventable diseases (VPDs), including polio, measles and rubella, yellow fever, Japanese encephalitis, rotavirus, and invasive bacterial diseases. In addition to providing high-quality laboratory surveillance data to help guide disease control, elimination, and eradication programs, these global networks provide capacity-building and an infrastructure for public health laboratories...
July 1, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28837840/development-of-a-recombinant-yellow-fever-vector-expressing-a-hiv-clade-c-founder-envelope-gp120
#8
Jae-Sung Yu, Hua-Xin Liao, Jamie Pritchett, Cindy Bowman, Callie Vivian, Robert Parks, Shi-Mao Xia, Melissa Cooper, Wilton B Williams, Mattia Bonsignori, Steven G Reed, Meng Chen, Nathan Vandergrift, Charles M Rice, Barton F Haynes
Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability of the YFV17D vector when carrying non-flavivirus genes has been problematic. We have constructed and expressed HIV-1 Env in YFV17D with either single transmembrane (STM) or double transmembrane (DTM) YFV E protein domains for the development of anti-HIV antibodies. Here we describe modifications of the YFV17D vector such that HIV-1 Env gp120 is expressed in up to 5 passages in Vero cells...
August 31, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28827760/protein-structure-shapes-immunodominance-in-the-cd4-t-cell-response-to-yellow-fever-vaccination
#9
Maximilian Koblischke, Maria S Mackroth, Julia Schwaiger, Ingrid Fae, Gottfried Fischer, Karin Stiasny, Franz X Heinz, Judith H Aberle
The live attenuated yellow fever (YF) vaccine is a highly effective human vaccine and induces long-term protective neutralizing antibodies directed against the viral envelope protein E. The generation of such antibodies requires the help of CD4 T cells which recognize peptides derived from proteins in virus particles internalized and processed by E-specific B cells. The CD4 T helper cell response is restricted to few immunodominant epitopes, but the mechanisms of their selection are largely unknown. Here, we report that CD4 T cell responses elicited by the YF-17D vaccine are focused to hotspots of two helices of the viral capsid protein and to exposed strands and loops of E...
August 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28822782/yellow-fever-vaccination-estimating-coverage
#10
Annelies Wilder-Smith
No abstract text is available yet for this article.
August 16, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28822780/global-yellow-fever-vaccination-coverage-from-1970-to-2016-an-adjusted-retrospective-analysis
#11
Freya M Shearer, Catherine L Moyes, David M Pigott, Oliver J Brady, Fatima Marinho, Aniruddha Deshpande, Joshua Longbottom, Annie J Browne, Moritz U G Kraemer, Kathleen M O'Reilly, Joachim Hombach, Sergio Yactayo, Valdelaine E M de Araújo, Aglaêr A da Nóbrega, Jonathan F Mosser, Jeffrey D Stanaway, Stephen S Lim, Simon I Hay, Nick Golding, Robert C Reiner
BACKGROUND: Substantial outbreaks of yellow fever in Angola and Brazil in the past 2 years, combined with global shortages in vaccine stockpiles, highlight a pressing need to assess present control strategies. The aims of this study were to estimate global yellow fever vaccination coverage from 1970 through to 2016 at high spatial resolution and to calculate the number of individuals still requiring vaccination to reach population coverage thresholds for outbreak prevention. METHODS: For this adjusted retrospective analysis, we compiled data from a range of sources (eg, WHO reports and health-service-provider registeries) reporting on yellow fever vaccination activities between May 1, 1939, and Oct 29, 2016...
August 16, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28811340/type-iii-interferon-mediated-signaling-is-critical-for-controlling-live-attenuated-yellow-fever-virus-infection-in-vivo
#12
Florian Douam, Yentli E Soto Albrecht, Gabriela Hrebikova, Evita Sadimin, Christian Davidson, Sergei V Kotenko, Alexander Ploss
Yellow fever virus (YFV) is an arthropod-borne flavivirus, infecting ~200,000 people worldwide annually and causing about 30,000 deaths. The live attenuated vaccine strain, YFV-17D, has significantly contributed in controlling the global burden of yellow fever worldwide. However, the viral and host contributions to YFV-17D attenuation remain elusive. Type I interferon (IFN-α/β) signaling and type II interferon (IFN-γ) signaling have been shown to be mutually supportive in controlling YFV-17D infection despite distinct mechanisms of action in viral infection...
August 15, 2017: MBio
https://www.readbyqxmd.com/read/28810279/-severe-yellow-fever-vaccine-associated-disease-a-case-report-and-current-overview
#13
Günther Slesak, Martin Gabriel, Cristina Domingo, Johannes Schäfer
History and physical examination A 56-year-old man developed high fever with severe headaches, fatigue, impaired concentration skills, and an exanthema 5 days after a yellow fever (YF) vaccination. Laboratory tests Liver enzymes and YF antibody titers were remarkably elevated. YF vaccine virus was detected in urine by PCR. Diagnosis and therapy Initially, severe YF vaccine-associated visceral disease was suspected and treated symptomatically. Clinical Course His fever ceased after 10 days in total, no organ failure developed...
August 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28806786/an-economic-evaluation-of-vector-control-in-the-age-of-a-dengue-vaccine
#14
Christopher Fitzpatrick, Alexander Haines, Mathieu Bangert, Andrew Farlow, Janet Hemingway, Raman Velayudhan
INTRODUCTION: Dengue is a rapidly emerging vector-borne Neglected Tropical Disease, with a 30-fold increase in the number of cases reported since 1960. The economic cost of the illness is measured in the billions of dollars annually. Environmental change and unplanned urbanization are conspiring to raise the health and economic cost even further beyond the reach of health systems and households. The health-sector response has depended in large part on control of the Aedes aegypti and Ae...
August 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28754189/progress-and-works-in-progress-update-on-flavivirus-vaccine-development
#15
REVIEW
Matthew H Collins, Stefan W Metz
Most areas of the globe are endemic for at least one flavivirus, putting billions at risk for infection. This diverse group of viral pathogens causes a range of manifestations in humans from asymptomatic infection to hemorrhagic fever to encephalitis to birth defects and even death. Many flaviviruses are transmitted by mosquitos and have expanded in geographic distribution in recent years, with dengue virus being the most prevalent, infecting approximately 400 million people each year. The explosive emergence of Zika virus in Latin America in 2014 refocused international attention on this medically important group of viruses...
July 25, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28753671/self-reported-infections-during-international-travel-and-notifiable-infections-among-returning-international-travellers-sweden-2009-2013
#16
Viktor Dahl, Anders Wallensten
We studied food and water-borne diseases (FWDs), sexually transmitted diseases (STDs), vector-borne diseases (VBDs) and diseases vaccinated against in the Swedish childhood vaccination programme among Swedish international travellers, in order to identify countries associated with a high number of infections. We used the national database for notifiable infections to estimate the number of FWDs (campylobacteriosis, salmonellosis, giardiasis, shigellosis, EHEC, Entamoeba histolytica, yersinosis, hepatitis A, paratyphoid fever, typhoid fever, hepatitis E, listeriosis, cholera), STIs (chlamydia, gonorrhoea and acute hepatitis B), VBDs (dengue fever, malaria, West Nile fever, Japanese encephalitis and yellow fever) and diseases vaccinated against in the Swedish childhood vaccination programme (pertussis, measles, mumps, rubella, diphtheria) acquired abroad 2009-2013...
2017: PloS One
https://www.readbyqxmd.com/read/28749924/update-temporary-total-depletion-of-u-s-licensed-yellow-fever-vaccine-for-civilian-travelers-addressed-by-investigational-new-drug-use-of-imported-stamaril-vaccine
#17
Mark D Gershman, Mark J Sotir
Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the United States, has announced that their stock of YF-VAX is totally depleted as of July 24, 2017. YF-VAX for civilian use will be unavailable for ordering from Sanofi Pasteur until mid-2018, when their new manufacturing facility is expected to be completed. However, YF-VAX might be available at some clinics for several months, until remaining supplies at those sites are exhausted. In anticipation of this temporary total depletion, in 2016, Sanofi Pasteur submitted an expanded access investigational new drug application to the Food and Drug Administration to allow for importation and use of Stamaril...
July 28, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28746549/construction-and-characterization-of-a-recombinant-yellow-fever-virus-stably-expressing-gaussia-luciferase
#18
Telissa C Kassar, Tereza Magalhães, José V J S, Amanda G O Carvalho, Andréa N M R DA Silva, Sabrina R A Queiroz, Giovani R Bertani, Laura H V G Gil
Yellow fever is an arthropod-borne viral disease that still poses high public health concerns, despite the availability of an effective vaccine. The development of recombinant viruses is of utmost importance for several types of studies, such as those aimed to dissect virus-host interactions and to search for novel antiviral strategies. Moreover, recombinant viruses expressing reporter genes may greatly facilitate these studies. Here, we report the construction of a recombinant yellow fever virus (YFV) expressing Gaussia luciferase (GLuc) (YFV-GLuc)...
July 20, 2017: Anais da Academia Brasileira de Ciências
https://www.readbyqxmd.com/read/28742857/dna-immunisation-with-dengue-virus-e-protein-domains-i-ii-but-not-domain-iii-enhances-zika-west-nile-and-yellow-fever-virus-infection
#19
Jose L Slon Campos, Monica Poggianella, Sara Marchese, Monica Mossenta, Jyoti Rana, Francesca Arnoldi, Marco Bestagno, Oscar R Burrone
Dengue virus (DENV), the causative agent of dengue disease, is among the most important mosquito-borne pathogens worldwide. DENV is composed of four closely related serotypes and belongs to the Flaviviridae family alongside other important arthropod-borne viral pathogens such as Zika virus (ZIKV), West Nile virus (WNV) and Yellow Fever virus (YFV). After infection, the antibody response is mostly directed to the viral E glycoprotein which is composed of three structural domains named DI, DII and DIII that share variable degrees of homology among different viruses...
2017: PloS One
https://www.readbyqxmd.com/read/28719400/dengue-vaccines-implications-for-dengue-control
#20
Matthew L Robinson, Anna P Durbin
PURPOSE OF REVIEW: Dengue, the most common arbovirus, is an increasingly significant cause of morbidity worldwide. After decades of research, an approved tetravalent dengue vaccine is finally available. Models constructed using recently available vaccine efficacy data allow for a data-driven discussion of the potential impact of dengue vaccine deployment on global control. RECENT FINDINGS: Phase 3 efficacy trials demonstrated that the approved dengue vaccine, chimeric yellow fever-dengue-tetravalent dengue vaccine, has an efficacy of 60% against dengue illness of any severity...
July 14, 2017: Current Opinion in Infectious Diseases
keyword
keyword
101939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"